Filter posts

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest …

Experts Weigh In on the Dangers of Importing Foreign Price Controls

Experts recently gathered on Capitol Hill to discuss how importing foreign price controls will lead …

Greenwood: A Critical Medicare Policy Has Been Delayed. Let’s Use This Opportunity to Get It Right...

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …

Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innov...

In October of 2018, the Trump Administration outlined a proposal that would import foreign price …

Insurers and PBMs Limit Access to Safer Opioid Alternatives

Opioid abuse and addiction in America continues to ravish communities, families, and individuals across the …

India Compulsory License: A Times of India Article Says It's Not Helping the Poor

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with …